

TIDES EUROPE

Oligonucleotide & Peptide Therapeutics

16-18 November 2022
Austria Center Vienna
Delivered as Hybrid Event


**EUROPE'S #1 FORUM FOR
OLIGONUCLEOTIDE AND PEPTIDE
LEADERS TO BUILD SUCCESSFUL
PARTNERSHIPS AND ACCELERATE
NEW PRODUCTS TO MARKET**

Visionary Keynote Speakers for 2022!



An Update on R&D Activities at CureVac

Patrick Baumhof, Ph.D., Senior Vice President Technology,
CureVac AG



Using Human Genetics to Identify New Targets for RNAi Therapies

Paul Nioi, Ph.D., Vice President, Discovery and
Translational Research, Alnylam Pharmaceuticals



Responsive Peptides

Knud Jensen, Ph.D., Professor, Department
of Chemistry, University of Copenhagen,
Denmark



Oligonucleotides for Cardiovascular Disease

Sotirios Tsimikas, M.D., Senior Vice President of Global
Cardiovascular Development, Ionis Pharmaceuticals, USA



mRNA vaccines: Can they Fulfill the Promise?

Alfred von Krempelhuber, Germany Medical Head,
Moderna Therapeutics, Germany

REGISTER BY 28 OCTOBER AND SAVE UP TO £200!

TIDSEuropeEvent.com

EUROPE'S FLAGSHIP MEETING FOR OLIGONUCLEOTIDE AND PEPTIDE SCIENCE, TECHNOLOGY AND NETWORKING



500+
OLIGONUCLEOTIDE, PEPTIDE, mRNA,
GENE EDITING & DELIVERY EXPERTS

Fast-track your products to the clinic and beyond by collaborating with leading pharma, biotechs, academia and solution providers from Europe, North America and Asia.



100+
CASE STUDIES AND
NEW DATA PRESENTATIONS

Apply best practices and lessons learned from industry leaders working across the entire spectrum from discovery to clinic to CMC to manufacturing.



50+
LEADING EXHIBITORS

Connect with leading manufacturing, technology, and service providers to drive your promising therapeutic towards commercial success.







NEW CONTENT AND SESSIONS FOR 2022!

- "The Emergence of Enzymatic Protocols for Assembly of Long Oligonucleotides" **NEW SESSION**
- "Peptide-Drug Conjugates as Tumor Targeted Therapies" **NEW SESSION**
- "LNPs for Nucleic Acid Delivery" **NEW SESSION**
- "CMC Control Strategies and Impurity Evaluation for Complex and Emerging Oligonucleotide Therapeutics" **NEW WORKSHOP**
- "Hot Topics in the Improvement of Peptide Therapeutics" **NEW WORKSHOP**
- "Regulatory CMC Considerations for Oligonucleotides" **NEW WORKSHOP**

8:30		
Optional Pre-Conference Morning Workshops 09:00-12:00		
9:00	<p>Workshop #1: CMC Control Strategies and Impurity Evaluation for Complex and Emerging Oligonucleotide Therapeutics</p> <p>09:00 Workshop Co-Moderators' Welcome and Opening Remarks Thomas Rupp, Owner and Principal, Thomas Rupp Consulting AG, Germany Marc Lemaitre, Ph.D., Consultant, ML Consult, USA</p> <p>09:05 Process-related Impurities in Synthetic Oligonucleotides Categorisation and Origin Thomas Rupp, Owner and Principal, Thomas Rupp Consulting AG, Germany</p> <p>9:45 Impurities in Raw Materials and How They Affect Final Oligonucleotide API Hagen Cramer, Ph.D., Chief Production Officer, QurAlis, USA</p> <p>10:30 Short Networking Refreshment Break</p> <p>10:45 Control Strategies and Regulatory Considerations Marc Lemaitre, Ph.D., Consultant, ML Consult, USA</p> <p>11:30 Open Discussion and Q&A with Workshop Speakers</p> <p>12:00 Close of Workshop</p>	<p>Workshop will cover the following topics: This workshop will address early drug development and CMC for oligonucleotide therapeutics. Preparing for IND/IMPd is a critical and strategic step for successful start of clinical development. A detailed discussion of moving oligonucleotide therapeutics from discovery to clinical trials will include a description of CMC strategies for early clinical development, process development, raw materials selection and control, GMP synthesis, analytical controls and specifications.</p> <p>The workshop will cover chemistry and regulatory aspects addressing impurities and their control and a regulatory part addressing what is needed for the preparation of IND-IMPd dossiers based on existing guidelines. Participants will gain a basic understanding of the considerations and requirements for taking an oligonucleotide therapeutic into first-in-human clinical trials.</p> <p>Who should attend? Anyone interested in development of oligonucleotide therapeutics; Anyone interested in outsourcing the manufacturing of oligonucleotide therapeutics to a CMO / CRO. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management.</p>
9:00	<p>Workshop #2: Regulatory CMC Hot topics for Oligonucleotides</p> <p>09:00 Workshop Moderator's Welcome and Opening Remarks Christian Wetter, Ph.D., Portfolio Leader, Pharma Technical Regulatory, F. Hoffmann-La Roche Ltd., Switzerland</p> <p>09:15 Expediting the Development of Synthetic Therapeutic Oligonucleotides through the Application of Platform Approaches Dominik Altevogt, Ph.D., Associate Director Regulatory Affairs CMC, Novartis Pharma AG, Switzerland</p> <p>09:45 Solution Oligonucleotide APIs: Regulatory Considerations Christian Wetter, Ph.D., Portfolio Leader, Pharma Technical Regulatory, F. Hoffmann-La Roche Ltd., Switzerland</p> <p>10:15 Networking Refreshment Break</p> <p>10:45 CMC Aspects for Accelerated Approval Procedure – The EMA Toolbox Guidance René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, BfArM, Federal Institute for Drugs and Medical Devices, Germany</p> <p>11:15 Regulatory Intelligence and Interactions for Development and Late Phase Programs Jennifer Franklin, Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals, USA</p> <p>11:45 Discussion and Closing Remarks</p> <p>12:00 Close of Workshop</p>	<p>Workshop #3: Hot Topics in the Improvement of Peptide Therapeutics</p> <p>09:00 Workshop Moderator's Welcome and Opening Remarks Bruce Morimoto, Ph.D., Vice President, Drug Development, Alto Neuroscience, USA</p> <p>09:15 Enhancing Peptide Properties by Side-chain and Structural Modification Alastair Hay, Ph.D., Vice President, Peptides, Almac, United Kingdom</p> <p>09:45 Insights into Cell Penetration: Cyclic Davunetide As a Model System Bruce Morimoto, Ph.D., Vice President, Drug Development, Alto Neuroscience, USA</p> <p>10:15 Networking Refreshment Break</p> <p>10:45 Selected Examples on the Use of SPPS/CEPS in Scale-up of Peptides Stan van der Beelen, Ph.D., Scientist, Enzytag, The Netherlands</p> <p>11:15 Green Peptide Chemistry and Beyond: Holistic Approaches to Sustainable Peptide Manufacturing Michael Postlethwaite, Ph.D., Senior Director, Sales & Business Development, European Territories, AmbioPharm, Switzerland</p> <p>11:45 Discussion and Closing Remarks</p> <p>12:00 Close of Workshop</p>
Luncheon Spotlight Presentations		
12:00	<p>Highly Sensitive Characterization and Quantification of Oligonucleotide Impurities and Metabolites by LC-MS</p> <p>Stephen Lock, Ph.D., Senior Marketing and Market Development Manager, BioPharma, EMEAI, SCIEX, United Kingdom</p> 	<p>Oligonucleotide Manufacturing at Bachem AND Continuous Purification of Oligonucleotide APIs Using ContiChrom System</p> <p>Ralf Eisenhuth, Ph.D., Process Manager Chromatography and Technology Transfer Oligo, Bachem AG, Switzerland</p> <p>Joseph Fraone, Senior Business Development Manager, Bachem</p> 

Main Conference Keynote Session	
13:05	<p>Chairperson's Opening Remarks: An Update on New Oligonucleotide Drug Approvals and Chemistries Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, USA</p>
13:15	 <p>An Update on Discovery and R&D Activities at CureVac Patrick Baumhof, Ph.D., Senior Vice President Technology, CureVac AG</p>
13:45	 <p>mRNA vaccines: Can they Fulfill the Promise? Alfred von Krempelhuber, Germany Medical Head, Moderna Therapeutics, Germany</p>
14:15	 <p>Responsive Peptides Knud Jensen, Ph.D., Professor, Department of Chemistry, University of Copenhagen, Denmark</p>
14:45	<p>Networking Refreshment Break in Poster and Exhibit Hall</p>
15:30	 <p>Using Human Genetics to Identify New Targets for RNAi Therapies Paul Nioi, Ph.D., Vice President, Discovery and Translational Research, Alnylam Pharmaceuticals</p>
16:00	 <p>Oligonucleotides for Cardiovascular Disease Sotirios Tsimikas, M.D., Senior Vice President of Global Cardiovascular Development, Ionis Pharmaceuticals, USA</p>
16:30	<p>Gut-specific Peptide Therapeutics Markus Muttenthaler, Ph.D., Associate Professor, Neuropeptide Research, The University of Queensland and University of Vienna</p>
17:00	 <p>Networking Reception in Poster and Exhibit Hall</p> <p>Join fellow attendees, speakers, exhibitors, and poster presenters for a fun evening of scientific exchange and networking in the exhibit hall.</p> <p>Sponsored by:</p> 
18:30	<p>Close of Day One</p>

Morning Spotlight Presentation			
7:30	Enzyme Development for siRNA Production by Fragment Condensation Yusuku Hagiwara, Ph.D., Senior Scientist, Ajinomoto Bio-Pharma Services, Japan		
	Oligonucleotide Track	Peptide Track	Delivery of Macromolecules Track
	Oligonucleotide Chemistry, Manufacturing and Controls	Peptide Discovery, Preclinical and Clinical	Delivery Strategies for Oligonucleotides, Peptides and mRNA
8:10	Chairperson's Remarks Mike Webb, Ph.D., Founder and CEO, Mike Webb Pharma	Chairperson's Remarks Christian Becker, Ph.D., Professor and Head of the Institute of Biological Chemistry, University of Vienna	Chairperson's Remarks Mimoun Ayoub, Ph.D., VP, Global Head Sales and Key Account Management, CordenPharma International
8:15	European Update on CMC Requirements for Oligonucleotides René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, BfArM, Federal Institute for Drugs and Medical Devices, Germany	Chemical Space Guided Design of Peptide Drugs Clémence Delalande, Ph.D., Senior Scientist, GDBspace AG, Switzerland	Endosomal Escape Vehicle (EEV) Platform to Enhance the Functional Delivery of Oligonucleotides Leo Qian, Ph.D., Co-Founder and Vice President, Discovery Research, Entrada Therapeutics, USA
8:45	Development of Kilogram-Scale Convergent Liquid-Phase Synthesis of Oligonucleotides Xuan Zhou, Ph.D., Senior Scientist, Oligonucleotide Development, Biogen	The streaMLine Platform for Accelerated Peptide Clinical Candidate Identification Kristoffer Rigbolt, Ph.D., Chief Technology Officer, Gubra, Denmark	EDO Peptide Delivery of Exon 51 Skipping Oligonucleotide in Healthy Volunteers James McArthur, Ph.D., CEO and President, PepGen Inc., USA
9:15	Growing Pains: The Challenges of Long Oligonucleotide Synthesis Fred Briones, Ph.D., Associate Director, Chemistry, Tessera Therapeutics, USA	Therapeutic Targeting of Hdm2/HmX E3 Ligase in Cancer Cells with De Novo Cyclotides Julio A. Camarero, Ph.D., Professor, Pharmacology and Pharmaceutical Sciences, University of Southern California, USA	Overcoming Challenges To RNA Systemic Extrahepatic Delivery and Endosomal Escape With Peptide-Nucleotide Polyplexes Covadonga Paneda, Ph.D., Chief Development Officer, Altamira Therapeutics
9:45	Networking Refreshment Break in Poster and Exhibit Hall		
10:30	Novel Thiomorpholino Oligonucleotides (TMOs) As a Robust Next Generation Platform for Splice Switching Antisense Therapies Rakesh Naduvile Veedu, Ph.D., Associate Professor and Head, Precision Nucleic Acid Therapeutics Group, Murdoch University, Australia	Novel Chemistry Platform Technologies for Creating Next-generation Precision Immunotherapies Vijaya Pattabiraman, Ph.D., Co-founder and CTO, Bright Peak Therapeutics, Switzerland	Use of Next Generation AAVs to Target Specific Cell types in the CNS or Nanoparticles to Enhance Drug delivery into the CNS Robert Bowser, Ph.D., Chief Scientific Officer, Barrow Neurological Institute and Chairman, nVector, USA
11:00	Refractive Index as a PAT Tool to Monitor Solid Phase Oligonucleotide Synthesis John Lopez, Ph.D., Senior Expert Science & Technology, Novartis Pharma AG, Switzerland	Development of the B Cell Cancer Vaccine HER-Vaxx for the Treatment of Her-2 Expressing Cancers Nicholas Ede, Ph.D., Chief Technology Officer, Imugene Ltd., Australia	Bicyclic Peptide Transferrin Receptor 1 Ligands Conjugated to Oligonucleotide Therapeutics Improve Potency in Skeletal and Cardiac Muscle Brooke Anderson, Ph.D., Principal Scientist, Ionis Pharmaceuticals, USA

11:30	Transition to Spotlight Presentations		
11:35	<p>Synthetic Oligonucleotides Aren't Perfect: bioZen Oligo, Paired with HRMS, Elucidates What You're Missing Michael McGinley, Director of Applications, Phenomenex, USA</p> 	<p>Enabling Pharma 4.0 with OCELOT™ System Control Stefan Hyde, Automation Manager, Asahi Kasei Bioprocess America</p> 	<p>Peptides as Biopharmaceuticals - Challenges in Biophysical Analysis Anshuman Shukla, Ph.D., Technical Expert, Intertek Pharmaceutical Services</p> 
12:05	Networking Luncheon in Poster and Exhibit Hall		
13:25	<p>Purification and Analysis of Exceptional Oligos – A Case Study Jonas Wege, Application Specialist, Tosoh Bioscience, Germany</p> 	<p>Towards Unlocking Potential of Gene Therapy via applying Small Molecule Manufacturing Know-how and Technology Jale Muslehiddinoglu, Ph.D., Vice President of Strategic Innovation, ST Pharm, South Korea</p> 	<p>Developing Intuitive Software for Oligonucleotide Synthesis Daniel Öman, Senior System Engineer, Cytiva, Sweden</p> 
	Oligonucleotide Track	Peptide Track	Delivery of Macromolecules Track
	Oligonucleotide Chemistry, Manufacturing and Controls	Peptide Discovery, Preclinical and Clinical	Lipid Nanoparticles (LNPs) for Safe and Effective mRNA Drug Delivery
13:55	<p>Chairman's Remarks Yogesh Sanghvi, Ph.D., President, Rasayan, Inc., USA</p>	<p>Chairman's Remarks Gavin Bennett, Ph.D., Senior Director, Drug Development, Bicycle Therapeutics Ltd., United Kingdom</p>	<p>Chairman's Remarks Mimoun Ayoub, Ph.D., VP, Global Head Sales and Key Account Management, CordenPharma International</p>
14:00	<p>Supply Chain Constraints in the Oligonucleotide Market Asmara Agha, Head of Strategic Sourcing, Nitto AVECIA</p>	<p>Resetting the Immune System without Shutting it Down Roly Foulkes, Ph.D., Chief Scientific Officer, Revolo Biotherapeutics, United Kingdom</p>	<p>Considerations for Scaling Lipid Based Parenteral Nanomedicines Michael Parr, Ph.D., Director of Formulations and Process Development, Evonik, Canada</p>
14:30	<p>Sequence Confirmation of Long Oligonucleotides: Mass Spectrometric Investigations Michael Ruehl, Ph.D., Head of Quality Control Lab, BioSpring GmbH, Germany</p>	<p>Tides, T-Cells & Therapeutics: How Clonal Neoantigen Peptides Are Used to Develop a Targeted, Autologous Solid Cancer Treatment Andrew Kennedy, Ph.D., Head of Peptides, Achilles Therapeutics UK Limited</p>	<p>Guiding mRNA-LNP Drug Products from Early R&D Programs to the Market – Scale Up and Production of mRNA LNPs Andreas Wagner, Ph.D., Head of Liposome Technology, Polymun Scientific GmbH, Austria</p>

AGENDA

THURSDAY 17 NOVEMBER 2022

TIDES EUROPE
Oligonucleotide &
Peptide Therapeutics

	Oligonucleotide Track	Peptide Track	Delivery of Macromolecules Track
	The Emergence of Enzymatic Protocols for Assembly of Long Oligonucleotides	Peptide-Drug Conjugates as Tumor Targeted Therapies	Lipid Nanoparticles (LNPs) for Safe and Effective mRNA Drug Delivery
15:00	Breaking the Barrier to Long, High Purity Synthetic DNA J. William Efcavitch, Ph.D., Co-Founder & Chief Scientific Officer, Molecular Assemblies, USA	Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics Targeting Fibroblast Activation Protein in solid lesions Samuele Cazzamalli, Ph.D., Head of Small Molecule Therapeutics, Philochem AG, Switzerland	Supporting mRNA-LNP Drug Products from Early R&D Programs to the Market – Scale Up and Production of mRNA Key Lipids Matthieu Giraud, Ph.D., Global Director Peptide, Lipids and Carbohydrates Platforms, CordenPharma International, Switzerland
15:30	Networking Refreshment Break in Poster and Exhibit Hall		
16:00	High-efficiency Nucleic Acid Manufacturing Systems to Fulfil the Promise of Genomic Medicine Helge Zieler, Ph.D., Founder & President, Primordial Genetics, USA	Bicycle Conjugates to Target Solid Tumors Gavin Bennett, Ph.D., Senior Director, Drug Development, Bicycle Therapeutics Ltd., United Kingdom	mRNA-LNP Manufacturing Technologies – A Pilot Study Through a Microfluidic Approach Umberto Romeo, Head of R&D, CordenPharma Caponago, Italy
16:30	Technology for Biocatalytic Synthesis of Oligonucleotides Jill Caswell, Ph.D., Biology Team Leader, Almac Sciences, United Kingdom	Turning the Tide: Radiolabelled Peptides as New Targeting Moieties for the Treatment of Intractable Solid Tumours John Carney, Founder and CEO, iTheranostics, Switzerland	Targeted Delivery Approaches Targeted Delivery of Therapeutic Oligonucleotides to Muscles and CNS Guillaume Jacquot, Ph.D., Translational Research Manager, Vect-Horus, France
17:00	Panel Discussion with Drinks and Snacks: DIVERSITY, EQUITY & INCLUSION IN THE SCIENTIFIC COMMUNITY Discussion Facilitator: Asmara Agha, Head of Strategic Sourcing, Nitto Avecia Panelists: Helge Zieler, Ph.D., Founder & President, Primordial Genetics, USA Mike Webb, Ph.D., Founder and CEO, Mike Webb Pharma Beth Morgan, Head of Biopharma and Chemistries Business Development EMEA, Agilent Technologies Cyndi Moyo, Founder, Tidalbase and Founder, Lean In Vienna Chapter		
	Close of Day Two		

Morning Spotlight Presentation			
7:30	Novel Ionizable Lipid Library for Enabling Non-Viral Delivery Martin Rabel, Ph.D., Senior Field Application Scientist, Precision NanoSystems		
	Oligonucleotide Track	Peptide Track	mRNA Track
	Oligonucleotide Discovery, Preclinical and Clinical	Peptide Chemistry, Manufacturing and Controls	mRNA Discovery, Preclinical and Clinical
8:10	Chairperson's Remarks Troels Koch, Ph.D., Senior Vice President, Chemistry, MiNa Therapeutics, Denmark	Chairperson's Remarks Franziska Arnhold, Ph.D., Director Business Development, Bachem AG, Switzerland	Chairperson's Remarks Christoph Kroener, Ph.D., Director DNA Process Development & Cap Technology, BioNTech AG, Germany
8:15	RNA Therapeutics Modalities and Targeted Delivery Approaches for Developing Transformational Medicines for Patients Tamar Grossman, Ph.D., VP, Global Head of RNA & Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson, USA	New Tools for Chemoselective Disulfide Formation in Cysteinyll Peptides Fernando Albericio, Ph.D., Research Professor, School of Chemistry, University of Kwazulu-Natal, South Africa	Development of Broadly Protective Influenza Vaccines Using Nucleoside-modified mRNA Norbert Pardi, Ph.D., Research Assistant Professor of Medicine, University of Pennsylvania
8:45	GalAhead™: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes Dmitry Samarsky, Ph.D., Chief Technology Officer, Sirnaomics, USA	Technology Transfer of Multi peptides - A Case Study Pierre-Emmanuel Broutin, Ph.D., BU Development and Manufacturing Integrated Project Manager, PolyPeptide Group, France	mRNA Therapeutics for Treatment of Liver Fibrosis Wolfgang Grosse, Ph.D., Associate Director Protein Design, CureVac AG, Germany
9:15	Oligonucleotide Chemistry and Delivery Jayaprakash Nair, Ph.D., Senior Director, Chemistry and Delivery Science, Alnylam Pharmaceuticals, USA	Dasiglucagon The Journey from Compound to Commercial Product Frederik Barfoed Beck, Ph.D., Senior Outsourcing Manager, Zealand Pharma A/S, Denmark	Update on Personalized Cancer Therapy Using messenger RNA Christoph Kroener, Ph.D., Director DNA Process Development & Cap Technology, BioNTech AG, Germany
9:45	Networking Refreshment Break in Poster and Exhibit Hall		
10:30	Towards a Stereo Defined mRNAi Trigger: Phosphordithioates Avoid Undefined Stereo Centres in GalNAc-conjugated siRNA Lucas Bethge, Vice President and Group Leader Oligonucleotide Chemistry, Silence Therapeutics, Germany	A Cocktail of Multi PEGylated Peptides - A Case Study in Peptide GMP Process Development Audrey Parat, Ph.D., Project Chemist, PolyPeptide Group, France	EI-201: a Systemic mRNA LNP Vaccine for the Treatment of HPV16+ Cancers Stefaan De Koker, Ph.D., Vice President Discovery, eTheRNA Immunotherapies, Belgium

11:00	Oligonucleotide Therapeutics for Duchenne Muscular Dystrophy: Current Developments and Competition from Alternative Approaches Thomas Roberts, DPhil, Senior Research Scientist, Research Fellow and Group Leader, Department of Paediatrics, University of Oxford, United Kingdom	Green Solid-Phase Peptide Synthesis: From Idea to Phase 3 Production Daniel Sejer Pedersen, Ph.D., Senior Development Scientist, Chemical Development, Novo Nordisk A/S, Denmark	Modulation of Host Immunity in the Airways with Interferon Lambda Encoding mRNA Christian Plank, Ph.D., Chief Technology Officer, Ethris GmbH, Germany
11:30	Transition to Spotlight Presentations		
11:35	Discovering RNA Therapeutics with Abzu's Explainable AI Lykke Pedersen, Ph.D., Head of RNA Therapeutics, Abzu, Denmark 	A Single-Use Disposable Tray for Bulk Lyophilization of Polypeptides and Oligonucleotides Scott Ross, Global Product Specialist, W.L. Gore & Associates, Inc., USA 	Designing Oligonucleotide Separations Using Reverse Phase Resins Martin Deetz, Ph.D., Technical Laureate, DuPont 
12:05	Networking Luncheon in Poster and Exhibit Hall		
13:25	A Modern and Efficient Solution for Oligonucleotide Analysis Chris Knowles, Ph.D., Senior Application Scientist, Waters, United Kingdom 	Demystifying Oligonucleotides: From R&D to Process scale, QA/QC to Manufacturing Rebecca Konietzny, Biopharma Specialist, Manager Technical Coverage and Solution Team EMEA – Biopharma, Agilent Technologies Beth Morgan, Head of Biopharma and Chemistries Business Development EMEA, Agilent Technologies 	Creating a Comprehensive Toolbox for Oligonucleotide Drug Discovery and Development Lijuan Pang, Ph.D., Project Director, Discovery Services, WuXi AppTec  
	Oligonucleotide Track	Peptide Track	mRNA Track
	Oligonucleotide Discovery, Preclinical and Clinical	Peptide Chemistry, Manufacturing and Controls	mRNA Discovery to Manufacturing
13:55	Chairman's Remarks Meena, Ph.D., Vice President of Bioanalytical, DMPK and Biomarker Development, Stoke Therapeutics, USA	Chairman's Remarks Mimoun Ayoub, Ph.D., VP, Global Head Sales and Key Account Management, CordenPharma International	Chairman's Remarks David Estape, Senior Fellow, CRB Group
14:00	CIVI 008: An Orally Active LNA Drug Against PCSK9. Henrik Oerum, Ph.D., Founder and Chief Scientific Officer, CiVi Biopharma Inc., Denmark	Aspen's Green Continuous LPPSTM Method for the Manufacturing of Lanreotide: Control Strategy Considerations Ivo F. Eggen, Ph.D., Section Lead New Product Development - Development & Technical Support, Aspen Oss B.V., The Netherlands	Preclinical Safety and Efficacy Studies of mRNA Vaccine STP2104 Against SARS-CoV-2 Infections Joo-Sung James Yang, Ph.D., Vice President and Head of mRNA R&D, ST Pharm, South Korea

14:30	<p>Progress on Development of RNA Base Editing Technologies for Precision Medicines</p> <p>Gerard Platenburg, Ph.D., Chief Scientific Officer, ProQR Therapeutics, The Netherlands</p>	<p>Refractometry to Study the Kinetics of the Solid-Phase Peptide Synthesis Process</p> <p>Beatriz De La Torre, Ph.D., Research Professor, Laboratory of Medicine and Medical Sciences, University of KwaZulu-Natal, South Africa</p> <p>John Lopez, Ph.D., Senior Expert Science & Technology, Novartis Pharma AG, Switzerland</p>	<p>Unlocking the Power of mRNA: Strategies for Manufacturing & Purification</p> <p>Carla Eller, MSAT Biomanufacturing Engineer, Merck KGaA</p>
15:00	<p>Non-clinical and Early Clinical Progress with STK-001, A Potential Disease Modifying Therapy for Dravet Syndrome</p> <p>Meena, Ph.D., Vice President of Bioanalytical, DMPK and Biomarker Development, Stoke Therapeutics, USA</p>	<p>Exploration of PAT & Continuous Flow Applications in Peptide Synthesis</p> <p>Andreas Heindl, Ph.D., Research Scientist, Peptide Synthesis and Process Development, Corden Pharma, Germany</p>	<p>Challenges and Current Approaches Concerning RNA Analytics for mRNA Therapeutics and Vaccines</p> <p>Simon Klenk, Ph.D., Associate Director RNA Analytics, RNA Biochemistry & Manufacturing, BioNTech SA, Germany</p>
15:30	<p>Networking Refreshment Break in Poster and Exhibit Hall</p>		
16:00	<p>Circular RNA Aptamers as Therapeutics for Targeting Intracellular Proteins</p> <p>Jacob Litke, Ph.D., Chief Scientific Officer & Co-Founder, Chimerna Therapeutics, USA</p>	<p>Process Development of an Efficient Large-scale Manufacturing Process of a PEG-ylated Peptide: Pegcetacoplan</p> <p>Arne Berthelmann, Ph.D., Director R&D, Bachem AG, Switzerland</p>	<p>Efficient mRNA development and manufacturing – key considerations and best practices</p> <p>Aditi Mehta, Ph.D., Senior Manager, Head of mRNA Process & Delivery, Merck KGaA, Germany</p>
16:30	<p>Drugging the Genome™ with Precision Genetic Medicines: Developing PNAs into Biotherapeutics</p> <p>Dietrich Stephan, Ph.D., Chairman and CEO, NeuBase Therapeutics, Inc.</p>	<p>A Hybrid Liquid Phase Peptide Synthesis (LPPS) Facility</p> <p>Rick Spencer, Senior Advisor - Process Engineering, Eli Lilly Kinsale Limited, Ireland</p>	<p>Will mRNA Redefine the Bio-manufacturing of the Future?</p> <p>David Estape, Senior Fellow, CRB Group</p>
17:00	<p>Close of Conference</p>		

TIDES EUROPE 2022 ADVISORY BOARD

Oligonucleotide Chemistry Manufacturing and Controls

- Nadim Akhtar, Ph.D., Senior Principal Scientist -New Modalities, AstraZeneca, United Kingdom
- Alun Garner, Business Development Manager, Nucleic Acid Solutions Division, Agilent Technologies, Inc., USA
- Annekathrin Haberland, Ph.D., Director, Regulatory Affairs, Berlin Cures GmbH, Germany
- Marc Lemaitre, Ph.D., Consultant, ML Consult, USA
- Damien Mouvet, Senior Scientific Manager, Quality Assistance SA, Belgium
- Rachel Orr, GSK Fellow, Data Strategy and Design, GlaxoSmithKline R&D, United Kingdom
- Christoph Rosenbohm, Ph.D. Chief Technology Officer, Ceptur Therapeutics, Switzerland
- Thomas Rupp, Owner & Principal, Thomas Rupp Consulting, Germany
- Yogesh Sanghvi, Ph.D., President, Rasayan, USA
- Nicole del Canto, Director, Global Regulatory CMC, Biogen
- David Tew, Project Leader and GSK Senior Fellow, Advanced Manufacturing Technology, GlaxoSmithKline, United Kingdom
- Sridhar Vaddeboina, Ph.D., Senior Vice President- CMC, WAVE Life Sciences, USA
- Stefan Vonhoff, Ph.D., Vice President CMC, NOXXON Pharma AG, Germany

Oligonucleotide Discovery, Preclinical and Clinical

- Troels Koch, Ph.D., Senior Vice President, Chemistry, MiNa Therapeutics
- Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, USA
- Dmitry Samarsky, Ph.D., Chief Technology Officer, Sirnaomics, USA
- Punit Seth, Ph.D., SVP, Research, Alnylam Pharmaceuticals
- Jimmy Weterings, Ph.D., Principal Scientist, Oligonucleotide Chemistry, AstraZeneca, Sweden
- Shuling Guo, Ph.D., Vice President, Antisense Drug Discovery, Ionis Pharmaceuticals

Peptide Chemistry, Manufacturing and Controls

- Mimoun Ayoub, Ph.D., VP, Global Head Sales and Key Account Management, CordenPharma International
- Alastair Hay, Ph.D., Vice President, Peptides, Almac, United Kingdom
- Ewa Kowalska, Chemical Process Development Manager, API Development, Ipsen Manufacturing Ireland Ltd.
- Leila Malik, Ph.D., Senior CMC Project Manager, Zealand Pharma AS, Denmark
- Franziska Arnhold, Ph.D., Director Business Development, Bachem AG, Switzerland
- Neil Thompson, Group Commercial Director, PolyPeptide Group, Sweden
- Najib Maslouh, Ph.D., Peptide Industry Expert, Former VP at Apellis Pharmaceuticals and Bachem Americas

Peptide Discovery, Preclinical and Clinical

- Christian Becker, Ph.D., Professor and Head of the Institute of Biological Chemistry, University of Vienna
- Waleed Danho, Ph.D., Consultant, Danho & Associates, USA
- Jesse Z. Dong, Ph.D., Vice President, Peptide Chemistry, BioNTech US
- Jesper Lau, Ph.D., Vice President, Chemical Biology, Global Research, Novo Nordisk A/S, Denmark
- Les Miranda, Ph.D., Executive Director, R&D & CMC Operations, Amgen, USA
- Bruce Morimoto, Ph.D., Vice President, Drug Development, Alto Neuroscience, USA
- Rami Hannoush, Ph.D., Former Senior Group Leader and Current, Advisor, Genentech
- Fernando Albericio, Ph.D., Research Professor, School of Chemistry, University of Kwazulu-Natal, South Africa

mRNA Therapeutics and Vaccines

- Christoph Kröner, Ph.D., Director DNA Process Development & Cap Technology, BioNTech AG, Germany
- Joanna Rejman, Ph.D., Associate Director Neurologic and Pulmonary Diseases, Product Design & Formulation, CureVac AG, Germany
- Luis Brito, Ph.D., VP, Delivery Platform, Beam Therapeutics, USA

TIDES HOSTS THE HIGHEST CONCENTRATION OF SENIOR DECISION MAKERS IN THE INDUSTRY - DON'T MISS THIS OPPORTUNITY TO REACH YOUR IDEAL AUDIENCE

ASSOCIATE SPONSORS



EVENT SPONSORS



EXHIBITORS



FOR MORE INFORMATION ON HOW YOU CAN CONNECT WITH KEY BUYERS AT TIDES 2022, CONTACT:

(Companies B,C,D,FG,H,I) Michael Dunnet | 617-969-6173 | Michael.Dunnet@Informa.com
 (Companies A,E,J-Z) Michael Moriarty | 646-895-7412 | Michael.Moriarty@Informa.com

Register by 28 October and Save Up to £200! www.TIDSEuropeEvent.com

2022 REGISTRATION AND PRICING

IN-PERSON PASS		SAVE £200 Register by 28 October, 2022	
Industry Rates	DISCOUNT	STANDARD RATE	
Main Conference + Pre-conference Workshop	£2,899	£3,099	
Main Conference Only	£2,499	£2,699	
Poster Presentation Add On		£150	
Academic/Govt Rates*		SAVE £50 Register by 28 October, 2022	
Main Conference + Pre-conference Workshop	\$1,349	£1,399	
All Access Conference Pass	£949	£999	
Poster Presentation Add On	Free		

*Academic/Government rates are only extended to full-time employees of government, universities and university-affiliated hospitals with no industry affiliation.

VIRTUAL PASS		SAVE £200 Register by 28 October, 2022	
Industry Rates	DISCOUNT	STANDARD RATE	
Digital Experience Pass + Digital Workshop	£2,599	£2,799	
Digital Experience Pass	£2,199	£2,399	
Poster Presentation Add On		£150	
Academic/Govt Rates*		SAVE £50 Register by 28 October, 2022	
Digital Experience Pass + Digital Workshop	£1,249	£1,299	
Digital Experience Pass	£849	£899	
Poster Presentation Add On	Free		

BOOK NOW

POSTER PRESENTATIONS

Share your company's latest research by presenting a poster at TIDES Europe 2022. All posters are displayed inside the exhibition hall on 16-18 November. The deadline to submit a poster abstract is 21 October 2022.

[Learn More & Submit Poster Abstract](#)

GROUP DISCOUNTS:

Register a group of 3+ to receive additional savings. To register your group, please contact:

Jessica Purnell
 jessica.purnell@informa.com
 or +44 20 8052 2779

3 WAYS TO REGISTER



ONLINE:
[TIDESEuropeEvent.com](https://www.tidesevent.com)



CALL
 +44 20 8052 2779



EMAIL
register@informa.com